Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of $1.52, $0.31 better than the analyst estimate of $1.21. Revenue for the quarter came in at $91.14 million versus the consensus estimate of $91.63 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.